Search Results for: Loudspeakers multiple
provenge's principal competitor therapy was taxotere, a less costly injectable therapy indicated for treatment of various types of cancer. cdf opened its mcrpc fund in june , and, from that time until august , dendreon alone financed cdf's mcrpc fund. from june through , at dendreon's request and on multiple
for xtandi patients, and not others, because xtandi was the dominant ari drug for treatment of mcrpc. on july , , at astellas' request, cdf opened an ari fund. astellas alone financed cdf's ari fund. as cdf intended, xtandi patients received nearly all of the money that the fund disbursed. cdf's multiple...
https://www.justice.gov/usao-ma/pr/foundations-resolve-allegations-enabling-pharmaceutical-companies-pay-kickbacks-medicare